短時間作用型インスリンの世界市場レポート 2025年

短時間作用型インスリン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で144億7,000万米ドルに成長します。予測期間中の成長は、政府の取り組みや支援の増加、生産における急速な技術革新、インスリン療法の採用増加、個別化医療の拡大に起因すると考えられます。この期間に予想される主な動向には、インスリン送達デバイスや技術の発展、革新的な速効型インスリンアナログの開発、バイオシミラーの台頭、患者中心の治療へのシフト、インスリン製剤の改良などがあります。

1型糖尿病の有病率の上昇は、短時間作用型インスリン市場の成長を牽引すると予想されます。1型糖尿病は、体内でインスリン産生細胞が破壊される自己免疫疾患であり、生涯にわたるインスリン治療が必要となります。1型糖尿病の罹患率の増加は、遺伝的要因、環境的誘因、自己免疫疾患の増加の影響を受けています。短時間作用型インスリンは、迅速な血糖コントロールを提供し、身体の自然なインスリン反応を模倣することによって、この状態を管理する上で重要な役割を果たしています。例えば、糖尿病に関する認識を高めることを目的とした団体であるDiabetes Australiaは、2023年に、2022年には約13万4,000人のオーストラリア人が1型糖尿病を患っており、その数は13万5,423人に増加していると報告しています。その結果、1型糖尿病の有病率の増加が短時間作用型インスリン市場の拡大に拍車をかけています。

短時間作用型インスリン市場の主要企業は、インスリンポッドのような革新的な製品を開発し、インスリン送達を強化し、糖尿病患者のアドヒアランスを向上させています。インスリンポッドは、糖尿病管理のための持続的なインスリン注入を提供するチューブレスのウェアラブルインスリン送達システムです。2023年4月、米国の医療機器会社であるインスレット社は、成人の2型糖尿病患者向けに設計された先駆的な基礎インスリン専用ポッドであるOmnipod GOのFDA認可を取得しました。このチューブレスで装着可能なデバイスは、別のコントローラーを必要とせずに持続的にインスリンを投与します。毎日の注射の必要性をなくし、あらかじめプログラムされたインスリン速度を提供することで、Omnipod GOは糖尿病管理を簡素化します。使いやすいデザインと薬局での入手のしやすさは、患者とヘルスケア・プロバイダーの両方にとっての利便性を高め、革新的な技術によって糖尿病治療を進歩させるというインスレットのコミットメントを強化しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界短時間作用型インスリンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の短時間作用型インスリン市場：成長率分析
• 世界の短時間作用型インスリン市場の実績：規模と成長, 2019-2024
• 世界の短時間作用型インスリン市場の予測：規模と成長, 2024-2029, 2034F
• 世界短時間作用型インスリン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の短時間作用型インスリン市場処方別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 通常のインスリン
• 速効型インスリン
• 世界の短時間作用型インスリン市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイアル
• プレフィルドペン
• カートリッジ
• 世界の短時間作用型インスリン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 静脈内
• 世界の短時間作用型インスリン市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 1型糖尿病
• 2型糖尿病
• 世界の短時間作用型インスリン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬局
• 病院薬局
• オンライン薬局
• 世界の短時間作用型インスリン市場レギュラーインスリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒトレギュラーインスリン
• 動物由来レギュラーインスリン
• その他の通常のインスリン
• 世界の短時間作用型インスリン市場速効型インスリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリンリスプロ
• インスリンアスパルト
• インスリングルリジン

第7章 地域別・国別分析

• 世界の短時間作用型インスリン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の短時間作用型インスリン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 短時間作用型インスリン市場：競合情勢
• 短時間作用型インスリン市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sumitomo Pharma Co. Ltd.
• Biocon Limited
• Kissei Pharmaceutical Co. Ltd.
• Lupin Limited
• Wockhardt Ltd.
• Lannett Co. Inc.
• MannKind Corporation
• Sihuan Pharmaceutical Holdings Group Ltd.
• Julphar（Gulf Pharmaceutical Industries）
• Geropharm LLC
• Bioton S.A.
• hec pharm co. ltd
• ADOCIA SAS
• Gan & Lee Pharmaceuticals Co. Ltd.
• Adocia S.A.S.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 短時間作用型インスリン市場2029：新たな機会を提供する国
• 短時間作用型インスリン市場2029：新たな機会を提供するセグメント
• 短時間作用型インスリン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Short-acting insulin is a type of insulin used to manage blood sugar levels during or after meals. It begins acting within 30 minutes to 1 hour, peaks around 2-3 hours, and lasts for approximately 4-6 hours. This insulin type plays a crucial role in glucose regulation by promoting glucose uptake into cells for energy, particularly after food consumption.

The main formulations of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin variant used to control blood sugar levels, typically administered before meals. These formulations are available in various dosage forms, including vials, pre-filled pens, and cartridges, and can be administered via subcutaneous or intravenous routes. Short-acting insulin is prescribed for both type 1 and type 2 diabetes patients and is distributed through retail pharmacies, hospital pharmacies, and online pharmacies.

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides short-acting insulin market statistics, including the short-acting insulin industry global market size, regional shares, competitors with the short-acting insulin market share, detailed short-acting insulin market segments, market trends, and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The short-acting insulin market size has grown strongly in recent years. It will grow from $11.00 billion in 2024 to $11.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the increasing type 1 diabetes population, a rising geriatric population, a surge in research and development funding, a higher prevalence of diagnosed cases, and growing urbanization.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to increased government initiatives and support, rapid innovations in production, the rising adoption of insulin therapy, and the expansion of personalized medicine. Key trends expected during this period include advancements in insulin delivery devices and technologies, the development of innovative fast-acting insulin analogs, the rise of biosimilars, a shift toward patient-centric care, and improvements in insulin formulation.

The rising prevalence of type 1 diabetes is expected to drive the growth of the short-acting insulin market. Type 1 diabetes is an autoimmune condition in which the body destroys insulin-producing cells, necessitating lifelong insulin therapy. The increasing incidence of type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin plays a crucial role in managing the condition by providing rapid blood sugar control and mimicking the body's natural insulin response. For example, in 2023, Diabetes Australia, an organization dedicated to raising awareness about diabetes, reported that approximately 134,000 Australians were living with type 1 diabetes in 2022, a number that increased to 135,423 in 2023. As a result, the growing prevalence of type 1 diabetes is fueling the expansion of the short-acting insulin market.

Leading companies in the short-acting insulin market are developing innovative products such as insulin pods to enhance insulin delivery and improve adherence for diabetes patients. An insulin pod is a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. In April 2023, Insulet Corporation, a US-based medical device company, received FDA clearance for Omnipod GO, a pioneering basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device delivers continuous insulin without requiring a separate controller. By eliminating the need for daily injections and offering pre-programmed insulin rates, Omnipod GO simplifies diabetes management. Its user-friendly design and pharmacy accessibility enhance convenience for both patients and healthcare providers, reinforcing Insulet's commitment to advancing diabetes care through innovative technology.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired the Humulin range in India from Eli Lilly & Company for an undisclosed amount. This acquisition strengthens Lupin's position in the Indian insulin market by expanding its product portfolio with the addition of Huminsulin from Eli Lilly & Company. Eli Lilly & Company, a US-based pharmaceutical firm, specializes in insulin products, including short-acting insulin, further reinforcing Lupin's commitment to providing comprehensive diabetes care solutions.

Major players in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., and Adocia S.A.S.

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short-acting insulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short-Acting Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short-acting insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short-acting insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The short-acting insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation: Regular Insulin; Rapid-Acting Insulin
• 2) By Dosage Form: Vials; Pre-filled Pens; Cartridges
• 3) By Route Of Administration: Subcutaneous; Intravenous
• 4) By Patient Type: Type 1 Diabetes; Type 2 Diabetes
• 5) By Distribution Channel: Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Regular Insulin: Human Regular Insulin; Animal-Derived Regular Insulin; Other Regular Insulin
• 2) By Rapid-Acting Insulin: Insulin Lispro; Insulin Aspart; Insulin Glulisine
• Companies Mentioned: Sanofi S.A.; Eli Lilly and Company; Novo Nordisk A/S; Baxter International Inc.; Eisai Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Short-Acting Insulin Market Characteristics

3. Short-Acting Insulin Market Trends And Strategies

4. Short-Acting Insulin Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Short-Acting Insulin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Short-Acting Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Short-Acting Insulin Market Growth Rate Analysis
• 5.4. Global Short-Acting Insulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Short-Acting Insulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Short-Acting Insulin Total Addressable Market (TAM)

6. Short-Acting Insulin Market Segmentation

• 6.1. Global Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Insulin
• Rapid-Acting Insulin
• 6.2. Global Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials
• Pre-filled Pens
• Cartridges
• 6.3. Global Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• 6.4. Global Short-Acting Insulin Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• 6.5. Global Short-Acting Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.6. Global Short-Acting Insulin Market, Sub-Segmentation Of Regular Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Regular Insulin
• Animal-Derived Regular Insulin
• Other Regular Insulin
• 6.7. Global Short-Acting Insulin Market, Sub-Segmentation Of Rapid-Acting Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Lispro
• Insulin Aspart
• Insulin Glulisine

7. Short-Acting Insulin Market Regional And Country Analysis

• 7.1. Global Short-Acting Insulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Short-Acting Insulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short-Acting Insulin Market

• 8.1. Asia-Pacific Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short-Acting Insulin Market

• 9.1. China Short-Acting Insulin Market Overview
• 9.2. China Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short-Acting Insulin Market

• 10.1. India Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short-Acting Insulin Market

• 11.1. Japan Short-Acting Insulin Market Overview
• 11.2. Japan Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short-Acting Insulin Market

• 12.1. Australia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short-Acting Insulin Market

• 13.1. Indonesia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short-Acting Insulin Market

• 14.1. South Korea Short-Acting Insulin Market Overview
• 14.2. South Korea Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short-Acting Insulin Market

• 15.1. Western Europe Short-Acting Insulin Market Overview
• 15.2. Western Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short-Acting Insulin Market

• 16.1. UK Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short-Acting Insulin Market

• 17.1. Germany Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short-Acting Insulin Market

• 18.1. France Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short-Acting Insulin Market

• 19.1. Italy Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short-Acting Insulin Market

• 20.1. Spain Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short-Acting Insulin Market

• 21.1. Eastern Europe Short-Acting Insulin Market Overview
• 21.2. Eastern Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short-Acting Insulin Market

• 22.1. Russia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short-Acting Insulin Market

• 23.1. North America Short-Acting Insulin Market Overview
• 23.2. North America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short-Acting Insulin Market

• 24.1. USA Short-Acting Insulin Market Overview
• 24.2. USA Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short-Acting Insulin Market

• 25.1. Canada Short-Acting Insulin Market Overview
• 25.2. Canada Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short-Acting Insulin Market

• 26.1. South America Short-Acting Insulin Market Overview
• 26.2. South America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short-Acting Insulin Market

• 27.1. Brazil Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short-Acting Insulin Market

• 28.1. Middle East Short-Acting Insulin Market Overview
• 28.2. Middle East Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short-Acting Insulin Market

• 29.1. Africa Short-Acting Insulin Market Overview
• 29.2. Africa Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short-Acting Insulin Market Competitive Landscape And Company Profiles

• 30.1. Short-Acting Insulin Market Competitive Landscape
• 30.2. Short-Acting Insulin Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Short-Acting Insulin Market Other Major And Innovative Companies

• 31.1. Sumitomo Pharma Co. Ltd.
• 31.2. Biocon Limited
• 31.3. Kissei Pharmaceutical Co. Ltd.
• 31.4. Lupin Limited
• 31.5. Wockhardt Ltd.
• 31.6. Lannett Co. Inc.
• 31.7. MannKind Corporation
• 31.8. Sihuan Pharmaceutical Holdings Group Ltd.
• 31.9. Julphar(Gulf Pharmaceutical Industries)
• 31.10. Geropharm LLC
• 31.11. Bioton S.A.
• 31.12. hec pharm co. ltd
• 31.13. ADOCIA SAS
• 31.14. Gan & Lee Pharmaceuticals Co. Ltd.
• 31.15. Adocia S.A.S.

32. Global Short-Acting Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short-Acting Insulin Market

34. Recent Developments In The Short-Acting Insulin Market

35. Short-Acting Insulin Market High Potential Countries, Segments and Strategies

• 35.1 Short-Acting Insulin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Short-Acting Insulin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Short-Acting Insulin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer